Wilson disease - Update on pathophysiology and management

Ceska a Slovenska Gastroenterologie a Hepatologie

Volumn 62, Issue 4, 2008, Pages 221-228

  Huster, Dominik ^a   Leonhardt, Karoline ^a   Mössner, Joachim ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

ATP7B; Central nervous system; Copper; Liver; Toxicity

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CERULOPLASMIN; CHELATING AGENT; MENKES PROTEIN; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; WILSON DISEASE PROTEIN; ZINC DERIVATIVE;

ANEMIA; AUTOIMMUNE DISEASE; CERULOPLASMIN BLOOD LEVEL; CHROMOSOME 13; CHRONIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; COPPER METABOLISM; DESCEMET MEMBRANE; DIET THERAPY; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG TOXICITY; DYSARTHRIA; DYSPEPSIA; ECHOGRAPHY; FETUS RISK; GENE MUTATION; GENE THERAPY; GENETIC SCREENING; GENETICS; HEALTH SURVEY; HUMAN; INHERITANCE; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY; PROGNOSIS; REVIEW; SCORING SYSTEM; SCREENING; SIDE EFFECT; STEM CELL TRANSPLANTATION; TERATOGENICITY; TREATMENT OUTCOME; TREMOR; WILSON DISEASE;

EID: 51949087168     PISSN: 1213323X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med 2000; 223: 39-46.
2. Schumann K, Classen HG, Dieter HH, et al. Hohenheim consensus workshop: copper. Eur J Clin Nutr 2002; 56: 469-483.
3. Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 2003; 57: 386-398.
4. Roberts EA, Cox DW. Wilson disease. Baillieres Clin Gastroenterol 1998; 12: 237-256.
5. Shim H, Harris ZL. Genetic defects in copper metabolism. J Nutr 2003; 133: 1527S-1531S.
6. Strausak D, Mercer JF, Dieter HH, et al. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res.Bull. 2001; 55: 175-185.
7. Rae TD, Schmidt PJ, Pufahl RA, et al. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 1999; 284: 805-808.
8. Field LS, Luk E, Culotta VC. Copper chaperones: personal escorts for metal ions. J Bioenerg Biomembr 2002; 34: 373-379.
9. Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 2003; 189: 147-163.
10. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161-1208.
11. Britton RS. Metal-induced hepatotoxicity. Semin Liver Dis 1996; 16: 3-12.
12. Lutsenko S, Efremov RG, Tsivkovskii R, Walker JM. Human copper-transporting ATPase ATP7B (the Wilson's disease protein): biochemical properties and regulation. J Bioenerg Biomembr 2002; 34: 351-362.
13. Linder MC, Wooten L, Cerveza P, et al. Copper transport. Am J Clin Nutr 1998; 67: 965S-971S.
14. Hoogenraad TU. Wilson's Disease. Intermed Medical Publishers, 2001.
15. Bearn AG. Genetic and biochemical aspects of Wilson's disease. Am J Med 1953; 15: 442-449.
16. Schilsky ML. Wilson disease: genetic basis of copper toxicity and natural history. Semin.Liver Dis 1996; 16: 83-95.
17. Brewer GJ. Wilson's disease. A clinician's guide to recognition, diagnosis, and management. Kluwer Academic Publishers, 2001.
18. Kenney SM, Cox DW. Sequence variation database for the Wilson disease copper transporter, ATP7B. Hum Mutat 2007; 28: 1171-1177.
19. Tsivkovskii R, Efremov RG, Lutsenko S. The role of the invariant His1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B. J Biol Chem 2003; 278: 13302-13308.
20. Huster D, Hoppert M, Lutsenko S, et al. Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology 2003; 124: 335-345.
21. Forbes JR, Cox DW. Copper-dependent trafficking of wilson disease mutant ATP7B proteins. Hum Mol Genet 2000; 9: 1927-1935.
22. Forbes JR, Cox DW. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 1998; 63: 1663-1674.
23. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006; 120: 151-159.
24. Polakova H, Katrincsakova B, Minarik G, et al. Detection of His 1069Gln mutation in Wilson disease by bidirectional PCR amplification of specific alleles (BI-PASA) test. Gen Physiol Biophys 2007; 26: 91-96.
25. Vrabelova S, Letocha O, Borsky M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab 2005; 86: 277-285.
26. Caca K, Ferenci P, Kuhn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 2001; 35: 575-581.
27. Cox D, Prat L, Walshe JM, et al. The importance of molecular diagnosis for Wilson Disease. Hepatology 2003; 38: 230A.
28. Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004; 19: 229-239.
29. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37: 1475-1492.
30. Langner C, Denk H. Wilson disease. Virchows Arch 2004; 445: 111-118.
31. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver 2003; 23: 139-142.
32. Vogel W, Kathrein H, Dietze O, Judmaier G. Ultrasonography in Wilson disease. Ann Intern Med 1988; 108: 769-770.
33. Vogl T, Steiner S, Hahn D, Schedel H, Lissner J. Diffuse liver parenchymal diseases: the value of MRI compared to sonography and CT. Rofo 1991; 154: 495-503.
34. Sturniolo GC, Mestriner C, Irato P, et al. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol 1999; 94: 334-338.
35. Sternlieb I. Wilson's disease and pregnancy (editorial; comment). Hepatology 2000; 31: 531-532.
36. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63: 521-527.
37. Siegemund R, Gunther K, Kuhn HJ, Lossner J. Medikamentöse Beeinflussung der Bioverfügbarkeit von Kupfer. Zentralblatt für Pharmakologie, Pharmakotherapie und Labordiagnostik 1988; 127: 239-240.
38. Hill GM, Brewer GJ, Juni JE, et al. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. Am J Med Sci 1986; 292: 344-349.
39. Schumacher G, Platz KP, Mueller AR, et al. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin Transplant 1997; 11: 217-224.
40. Geissler I, Heinemann K, Rohm S, et al. Liver transplantation for hepatic and neurological Wilson's disease. Transplant Proc 2003; 35: 1445-1446.
41. Irani AN, Malhi H, Slehria S, et al. S. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 2001; 3: 302-309.
42. Ha-Hao D, Merle U, Hofmann C, et al. Chances and shortcomins of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 2002; 40: 209-216.
43. Merle U, Stremmel W, Encke J. Perspectives for gene therapy of Wilson disease. Curr Gene Ther 2007; 7: 217-220.
44. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson disease - a cohort study. Gut 2007; 56: 115-120.